Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction
- Conditions
- Congestive Heart Failure
- Interventions
- Drug: HTEA
- Registration Number
- NCT02292043
- Lead Sponsor
- Harbin Medical University
- Brief Summary
The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.
- Detailed Description
The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- 90 chronic cardiac failure patients in our hospital were selected and divided into two groups.
- Vavular diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description post-myocardial infarction group HTEA post-myocardial infarction group treated with TEA idiopathic dilated cardiomyopathy group HTEA idiopathic dilated cardiomyopathy group treated with HTEA
- Primary Outcome Measures
Name Time Method Morbidity 1 months to 3 months after discharge
- Secondary Outcome Measures
Name Time Method The decreased degree of NT-proBNP higher than 30% 3 months after discharge
Trial Locations
- Locations (2)
Ren Xiaohui
🇨🇳Harbin, Heilongjiang, China
the first affiliated hospital of Harbin Medical University
🇨🇳Harbin, Heilongjiang, China